Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 239


A Dietary Ketone Ester Normalizes Abnormal Behavior in a Mouse Model of Alzheimer's Disease.

Pawlosky RJ, Kashiwaya Y, King MT, Veech RL.

Int J Mol Sci. 2020 Feb 4;21(3). pii: E1044. doi: 10.3390/ijms21031044.


Systematic review of clinical practice guidelines for colorectal and anal cancer: the extent of recommendations for managing long-term symptoms and functional impairments.

Wiltink LM, White K, King MT, Rutherford C.

Support Care Cancer. 2020 Feb 5. doi: 10.1007/s00520-020-05301-7. [Epub ahead of print] Review.


Role of a noncanonical disulfide bond in the stability, affinity, and flexibility of a VHH specific for the Listeria virulence factor InlB.

Mendoza MN, Jian M, King MT, Brooks CL.

Protein Sci. 2020 Jan 24. doi: 10.1002/pro.3831. [Epub ahead of print]


Predictors of progression free survival, overall survival and early cessation of chemotherapy in women with potentially platinum sensitive (PPS) recurrent ovarian cancer (ROC) starting third or subsequent line(≥3) chemotherapy - The GCIG symptom benefit study (SBS).

Roncolato FT, O'Connell RL, Joly F, Lanceley A, Hilpert F, Buizen L, Okamoto A, Aotani E, Salutari V, Donnellan P, Oza A, Avall-Lundqvist E, Berek J, Fehm T, Ledermann J, Roemer-Becuwe C, Stockler MR, King MT, Friedlander ML.

Gynecol Oncol. 2020 Jan;156(1):45-53. doi: 10.1016/j.ygyno.2019.10.001. Epub 2019 Dec 10.


Relationship between inorganic ion distribution, resting membrane potential, and the ΔG' of ATP hydrolysis: a new paradigm.

Veech RL, King MT, Pawlosky R, Bradshaw PC, Curtis W.

FASEB J. 2019 Dec;33(12):13126-13130. doi: 10.1096/fj.201901942R. Epub 2019 Nov 5.


U.K. utility weights for the EORTC QLU-C10D.

Norman R, Mercieca-Bebber R, Rowen D, Brazier JE, Cella D, Pickard AS, Street DJ, Viney R, Revicki D, King MT; European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Group and the MAUCa Consortium.

Health Econ. 2019 Dec;28(12):1385-1401. doi: 10.1002/hec.3950. Epub 2019 Sep 3.


Health-Related Quality of Life during Chemoradiation in Locally Advanced Rectal Cancer: Impacts and Ethnic Disparities.

Lim SH, Ip E, Ng W, Chua W, Asghari R, Roohullah A, Descallar J, Henderson C, Spring K, de Souza P, King MT.

Cancers (Basel). 2019 Aug 28;11(9). pii: E1263. doi: 10.3390/cancers11091263.


Practice Patterns and Outcomes Among Patients With N0M0 Prostate Cancer and a Very High Prostate-Specific Antigen Level.

Muralidhar V, Nguyen PL, Mahal BA, Yang DD, Mouw KW, Rose BS, Beard CJ, Efstathiou JA, Martin NE, King MT, Orio PF.

J Natl Compr Canc Netw. 2019 Aug 1;17(8):941-948. doi: 10.6004/jnccn.2018.7283.


Short communication: Assessing the accuracy of inline milk fat-to-protein ratio data as an indicator of hyperketonemia in dairy cows in herds with automated milking systems.

King MTM, Duffield TF, DeVries TJ.

J Dairy Sci. 2019 Sep;102(9):8417-8422. doi: 10.3168/jds.2018-16070. Epub 2019 Jul 10.


The EORTC QLU-C10D: The Canadian Valuation Study and Algorithm to Derive Cancer-Specific Utilities From the EORTC QLQ-C30.

McTaggart-Cowan H, King MT, Norman R, Costa DSJ, Pickard AS, Regier DA, Viney R, Peacock SJ.

MDM Policy Pract. 2019 Apr 13;4(1):2381468319842532. doi: 10.1177/2381468319842532. eCollection 2019 Jan-Jun.


The EORTC Quality of Life Questionnaire for cancer patients (QLQ-C30): Australian general population reference values.

Mercieca-Bebber R, Costa DS, Norman R, Janda M, Smith DP, Grimison P, Gamper EM, King MT.

Med J Aust. 2019 Jun;210(11):499-506. doi: 10.5694/mja2.50207. Epub 2019 Jun 2.


A PRDM16-Driven Metabolic Signal from Adipocytes Regulates Precursor Cell Fate.

Wang W, Ishibashi J, Trefely S, Shao M, Cowan AJ, Sakers A, Lim HW, O'Connor S, Doan MT, Cohen P, Baur JA, King MT, Veech RL, Won KJ, Rabinowitz JD, Snyder NW, Gupta RK, Seale P.

Cell Metab. 2019 Jul 2;30(1):174-189.e5. doi: 10.1016/j.cmet.2019.05.005. Epub 2019 May 30.


Combined External Beam Radiation Therapy and Brachytherapy versus Radical Prostatectomy with Adjuvant Radiation Therapy for Gleason 9-10 Prostate Cancer.

Muralidhar V, Mahal BA, Butler S, Lamba N, Yang DD, Leeman J, D'Amico AV, Nguyen PL, Trinh QD, Orio PF 3rd, King MT.

J Urol. 2019 Nov;202(5):973-978. doi: 10.1097/JU.0000000000000352. Epub 2019 Oct 9.


Active Surveillance for Low-Risk Prostate Cancer in Black Patients.

Butler S, Muralidhar V, Chavez J, Fullerton Z, Mahal A, Nezolosky M, Vastola M, Zhao SG, D'Amico AV, Dess RT, Feng FY, King MT, Mouw KW, Spratt DE, Trinh QD, Nguyen PL, Rebbeck TR, Mahal BA.

N Engl J Med. 2019 May 23;380(21):2070-2072. doi: 10.1056/NEJMc1900333. No abstract available.


Assessing quality of life in palliative care settings: head-to-head comparison of four patient-reported outcome measures (EORTC QLQ-C15-PAL, FACT-Pal, FACT-Pal-14, FACT-G7).

King MT, Agar M, Currow DC, Hardy J, Fazekas B, McCaffrey N.

Support Care Cancer. 2020 Jan;28(1):141-153. doi: 10.1007/s00520-019-04754-9. Epub 2019 Apr 16.


Can Methods Developed for Interpreting Group-level Patient-reported Outcome Data be Applied to Individual Patient Management?

King MT, Dueck AC, Revicki DA.

Med Care. 2019 May;57 Suppl 5 Suppl 1:S38-S45. doi: 10.1097/MLR.0000000000001111.


Systematic Evaluation of Patient-Reported Outcome Protocol Content and Reporting in Cancer Trials.

Kyte D, Retzer A, Ahmed K, Keeley T, Armes J, Brown JM, Calman L, Gavin A, Glaser AW, Greenfield DM, Lanceley A, Taylor RM, Velikova G, Brundage M, Efficace F, Mercieca-Bebber R, King MT, Turner G, Calvert M.

J Natl Cancer Inst. 2019 Nov 1;111(11):1170-1178. doi: 10.1093/jnci/djz038.


A comparative analysis of overall survival between high-dose-rate and low-dose-rate brachytherapy boosts for unfavorable-risk prostate cancer.

King MT, Yang DD, Muralidhar V, Mahal B, Butler S, Devlin PM, Lee LJ, Mouw KW, Martin NM, D'Amico AV, Nguyen PL, Orio PF 3rd.

Brachytherapy. 2019 Mar - Apr;18(2):186-191. doi: 10.1016/j.brachy.2018.12.007. Epub 2019 Jan 10.


Evaluating the influence of prostate-specific antigen kinetics on metastasis in men with PSA recurrence after partial gland therapy.

King MT, Nguyen PL, Boldbaatar N, Yang DD, Muralidhar V, Tempany CM, Cormack RA, Hurwitz MD, Suh WW, Pomerantz MM, D'Amico AV, Orio PF 3rd.

Brachytherapy. 2019 Mar - Apr;18(2):198-203. doi: 10.1016/j.brachy.2018.12.001. Epub 2019 Jan 10.


Reply to Partial gland therapy for prostate cancer.

King MT, Nguyen PL, D'Amico AV, Orio PF 3rd.

Cancer. 2019 Mar 1;125(5):819-820. doi: 10.1002/cncr.31822. Epub 2018 Dec 20. No abstract available.


Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9-10 Prostate Cancer.

Yang DD, Mahal BA, Muralidhar V, Martin NE, Orio PF, Mouw KW, King MT, Choueiri TK, Trinh QD, Hoffman KE, Spratt DE, Feng FY, Nguyen PL.

Eur Urol. 2019 Jan;75(1):35-41. doi: 10.1016/j.eururo.2018.08.033. Epub 2018 Oct 24.


The importance of patient-reported outcomes in clinical trials and strategies for future optimization.

Mercieca-Bebber R, King MT, Calvert MJ, Stockler MR, Friedlander M.

Patient Relat Outcome Meas. 2018 Nov 1;9:353-367. doi: 10.2147/PROM.S156279. eCollection 2018. Review.


Is quality of life a suitable measure of patient decision aid effectiveness? Sub-analysis of a Cochrane systematic review.

Rutherford C, King MT, Butow P, Legare F, Lyddiatt A, Souli I, Rincones O, Stacey D.

Qual Life Res. 2019 Mar;28(3):593-607. doi: 10.1007/s11136-018-2045-7. Epub 2018 Nov 13. Review.


Interpreting European Organisation for Research and Treatment for Cancer Quality of life Questionnaire core 30 scores as minimally importantly different for patients with malignant melanoma.

Musoro JZ, Bottomley A, Coens C, Eggermont AM, King MT, Cocks K, Sprangers MA, Groenvold M, Velikova G, Flechtner HH, Brandberg Y; EORTC Melanoma Group and EORTC Quality of Life Group.

Eur J Cancer. 2018 Nov;104:169-181. doi: 10.1016/j.ejca.2018.09.005. Epub 2018 Oct 22.


Examining Within-Person and Between-Person Associations of Family Violence and Peer Deviance on Bullying Perpetration among Middle School Students.

Grant N, Merrin GJ, King MT, Espelage DL.

Psychol Violence. 2019 Jan;9(1):18-27. doi: 10.1037/vio0000210. Epub 2018 Aug 2.


Milk yield relative to supplement intake and rumination time differs by health status for fresh cows milked with automated systems.

King MTM, Sparkman KJ, LeBlanc SJ, DeVries TJ.

J Dairy Sci. 2018 Nov;101(11):10168-10176. doi: 10.3168/jds.2018-14671. Epub 2018 Aug 23.


Test-Retest Reliability of Discrete Choice Experiment for Valuations of QLU-C10D Health States.

Gamper EM, Holzner B, King MT, Norman R, Viney R, Nerich V, Kemmler G.

Value Health. 2018 Aug;21(8):958-966. doi: 10.1016/j.jval.2017.11.012. Epub 2018 Mar 3.


Structural basis of VHH-mediated neutralization of the food-borne pathogen Listeria monocytogenes.

King MT, Huh I, Shenai A, Brooks TM, Brooks CL.

J Biol Chem. 2018 Aug 31;293(35):13626-13635. doi: 10.1074/jbc.RA118.003888. Epub 2018 Jul 5.


Long-term outcomes of partial prostate treatment with magnetic resonance imaging-guided brachytherapy for patients with favorable-risk prostate cancer.

King MT, Nguyen PL, Boldbaatar N, Tempany CM, Cormack RA, Beard CJ, Hurwitz MD, Suh WW, D'Amico AV, Orio PF 3rd.

Cancer. 2018 Sep 1;124(17):3528-3535. doi: 10.1002/cncr.31568. Epub 2018 Jul 5.


Graduate Student Literature Review: Detecting health disorders using data from automatic milking systems and associated technologies.

King MTM, DeVries TJ.

J Dairy Sci. 2018 Sep;101(9):8605-8614. doi: 10.3168/jds.2018-14521. Epub 2018 Jun 28. Review.


The EORTC CAT Core-The computer adaptive version of the EORTC QLQ-C30 questionnaire.

Petersen MA, Aaronson NK, Arraras JI, Chie WC, Conroy T, Costantini A, Dirven L, Fayers P, Gamper EM, Giesinger JM, Habets EJJ, Hammerlid E, Helbostad J, Hjermstad MJ, Holzner B, Johnson C, Kemmler G, King MT, Kaasa S, Loge JH, Reijneveld JC, Singer S, Taphoorn MJB, Thamsborg LH, Tomaszewski KA, Velikova G, Verdonck-de Leeuw IM, Young T, Groenvold M; European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Group.

Eur J Cancer. 2018 Sep;100:8-16. doi: 10.1016/j.ejca.2018.04.016. Epub 2018 Jun 21.


Determining optimal eluter design by modeling physical dose enhancement in brachytherapy.

Guthier CV, D'Amico AV, King MT, Nguyen PL, Orio PF, Sridhar S, Makrigiorgos GM, Cormack RA.

Med Phys. 2018 Jun 15. doi: 10.1002/mp.13051. [Epub ahead of print]


The administration of patient-reported outcome questionnaires in cancer trials: Interviews with trial coordinators regarding their roles, experiences, challenges and training.

Mercieca-Bebber R, Calvert M, Kyte D, Stockler M, King MT.

Contemp Clin Trials Commun. 2017 Nov 23;9:23-32. doi: 10.1016/j.conctc.2017.11.009. eCollection 2018 Mar.


Postoperative Concurrent Chemoradiotherapy Versus Postoperative Radiotherapy in High-Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck: The Randomized Phase III TROG 05.01 Trial.

Porceddu SV, Bressel M, Poulsen MG, Stoneley A, Veness MJ, Kenny LM, Wratten C, Corry J, Cooper S, Fogarty GB, Collins M, Collins MK, Macann AMJ, Milross CG, Penniment MG, Liu HY, King MT, Panizza BJ, Rischin D.

J Clin Oncol. 2018 May 1;36(13):1275-1283. doi: 10.1200/JCO.2017.77.0941. Epub 2018 Mar 14.


Behavior and productivity of cows milked in automated systems before diagnosis of health disorders in early lactation.

King MTM, LeBlanc SJ, Pajor EA, Wright TC, DeVries TJ.

J Dairy Sci. 2018 May;101(5):4343-4356. doi: 10.3168/jds.2017-13686. Epub 2018 Feb 15.


Evaluation of patient-reported outcome protocol content and reporting in UK cancer clinical trials: the EPiC study qualitative protocol.

Retzer A, Keeley T, Ahmed K, Armes J, Brown JM, Calman L, Copland C, Efficace F, Gavin A, Glaser A, Greenfield DM, Lanceley A, Taylor RM, Velikova G, Brundage M, Mercieca-Bebber R, King MT, Calvert M, Kyte D.

BMJ Open. 2018 Feb 3;8(2):e017282. doi: 10.1136/bmjopen-2017-017282.


PROMIS depression measures perform similarly to legacy measures relative to a structured diagnostic interview for depression in cancer patients.

Clover K, Lambert SD, Oldmeadow C, Britton B, King MT, Mitchell AJ, Carter G.

Qual Life Res. 2018 May;27(5):1357-1367. doi: 10.1007/s11136-018-1803-x. Epub 2018 Feb 8.


Guidelines for Inclusion of Patient-Reported Outcomes in Clinical Trial Protocols: The SPIRIT-PRO Extension.

Calvert M, Kyte D, Mercieca-Bebber R, Slade A, Chan AW, King MT; the SPIRIT-PRO Group, Hunn A, Bottomley A, Regnault A, Chan AW, Ells C, O'Connor D, Revicki D, Patrick D, Altman D, Basch E, Velikova G, Price G, Draper H, Blazeby J, Scott J, Coast J, Norquist J, Brown J, Haywood K, Johnson LL, Campbell L, Frank L, von Hildebrand M, Brundage M, Palmer M, Kluetz P, Stephens R, Golub RM, Mitchell S, Groves T.

JAMA. 2018 Feb 6;319(5):483-494. doi: 10.1001/jama.2017.21903.


Assessment of content validity for patient-reported outcome measures used in patients with non-muscle invasive bladder cancer: a systematic review.

Rutherford C, Patel MI, Tait MA, Smith DP, Costa DSJ, King MT.

Support Care Cancer. 2018 Apr;26(4):1061-1076. doi: 10.1007/s00520-018-4058-8. Epub 2018 Feb 1.


Establishing anchor-based minimally important differences (MID) with the EORTC quality-of-life measures: a meta-analysis protocol.

Musoro ZJ, Hamel JF, Ediebah DE, Cocks K, King MT, Groenvold M, Sprangers MAG, Brandberg Y, Velikova G, Maringwa J, Flechtner HH, Bottomley A, Coens C; EORTC Quality of Life Group.

BMJ Open. 2018 Jan 10;8(1):e019117. doi: 10.1136/bmjopen-2017-019117.


Brachytherapy monotherapy may be sufficient for a subset of patients with unfavorable intermediate risk prostate cancer.

King MT, Chen MH, Moran BJ, Braccioforte MH, Buzurovic I, Muralidhar V, Yang DD, Mouw KW, Devlin PM, D'Amico AV, Nguyen PL, Orio PF 3rd.

Urol Oncol. 2018 Apr;36(4):157.e15-157.e20. doi: 10.1016/j.urolonc.2017.11.022. Epub 2017 Dec 21.


Australian Utility Weights for the EORTC QLU-C10D, a Multi-Attribute Utility Instrument Derived from the Cancer-Specific Quality of Life Questionnaire, EORTC QLQ-C30.

King MT, Viney R, Simon Pickard A, Rowen D, Aaronson NK, Brazier JE, Cella D, Costa DSJ, Fayers PM, Kemmler G, McTaggart-Cowen H, Mercieca-Bebber R, Peacock S, Street DJ, Young TA, Norman R; MAUCa Consortium.

Pharmacoeconomics. 2018 Feb;36(2):225-238. doi: 10.1007/s40273-017-0582-5.


Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters-patient-centered end points in trials of maintenance therapy.

Friedlander M, Rau J, Lee CK, Meier W, Lesoin A, Kim JW, Poveda A, Buck M, Scambia G, Shimada M, Hilpert F, King MT, Debruyne P, Bologna A, Malander S, Monk BJ, Petru E, Calvert P, Herzog TJ, Barrett C, du Bois A.

Ann Oncol. 2018 Mar 1;29(3):737-743. doi: 10.1093/annonc/mdx796.


Lack of Apparent Survival Benefit With Use of Androgen Deprivation Therapy in Patients With High-risk Prostate Cancer Receiving Combined External Beam Radiation Therapy and Brachytherapy.

Yang DD, Muralidhar V, Mahal BA, Nguyen PL, Devlin PM, King MT, Orio PF 3rd.

Int J Radiat Oncol Biol Phys. 2018 Jan 1;100(1):53-58. doi: 10.1016/j.ijrobp.2017.08.046. Epub 2017 Sep 9.


Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer.

King MT, Stockler MR, O'Connell RL, Buizen L, Joly F, Lanceley A, Hilpert F, Okamoto A, Aotani E, Bryce J, Donnellan P, Oza A, Avall-Lundqvist E, Berek JS, Sehouli J, Feeney A, Berton-Rigaud D, Costa DSJ, Friedlander ML; GCIG Symptom Benefit group.

Qual Life Res. 2018 Jan;27(1):59-74. doi: 10.1007/s11136-017-1729-8. Epub 2017 Dec 16.


Pathologic Outcomes of Gleason 6 Favorable Intermediate-Risk Prostate Cancer Treated With Radical Prostatectomy: Implications for Active Surveillance.

Yang DD, Mahal BA, Muralidhar V, Vastola ME, Boldbaatar N, Labe SA, Nezolosky MD, Orio PF 3rd, King MT, Martin NE, Mouw KW, Trinh QD, Nguyen PL.

Clin Genitourin Cancer. 2018 Jun;16(3):226-234. doi: 10.1016/j.clgc.2017.10.013. Epub 2017 Nov 9.


Psychometric Evaluation of a Patient-Reported Symptom Index for Nonmuscle Invasive Bladder Cancer: Field Testing Protocol.

Rutherford C, King MT, Smith DP, Costa DS, Tait MA, Patel MI; NMIBC-SI Working Group.

JMIR Res Protoc. 2017 Nov 8;6(11):e216. doi: 10.2196/resprot.8761.


International validation of the European Organisation for Research and Treatment of Cancer QLQ-BRECON23 quality-of-life questionnaire for women undergoing breast reconstruction.

Winters ZE, Afzal M, Rutherford C, Holzner B, Rumpold G, da Costa Vieira RA, Hartup S, Flitcroft K, Bjelic-Radisic V, Oberguggenberger A, Panouilleres M, Mani M, Catanuto G, Douek M, Kokan J, Sinai P, King MT; European Organisation for Research and Treatment of Cancer Quality of Life Group.

Br J Surg. 2018 Feb;105(3):209-222. doi: 10.1002/bjs.10656. Epub 2017 Nov 8.


Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) - Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS).

Roncolato FT, Berton-Rigaud D, O'Connell R, Lanceley A, Sehouli J, Buizen L, Okamoto A, Aotani E, Lorusso D, Donnellan P, Oza A, Avall-Lundqvist E, Berek J, Hilpert F, Ledermann JA, Kaminsky MC, Stockler MR, King MT, Friedlander M.

Gynecol Oncol. 2018 Jan;148(1):36-41. doi: 10.1016/j.ygyno.2017.10.019. Epub 2017 Oct 26.


Lack of Benefit From the Addition of External Beam Radiation Therapy to Brachytherapy for Intermediate- and High-risk Prostate Cancer.

Yang DD, Muralidhar V, Nguyen PL, Buzurovic I, Martin NE, Mouw KW, Devlin PM, Trinh QD, Orio PF 3rd, King MT.

Int J Radiat Oncol Biol Phys. 2017 Nov 15;99(4):904-911. doi: 10.1016/j.ijrobp.2017.07.034. Epub 2017 Jul 31.


Supplemental Content

Support Center